Sionna was founded in 2019 and is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in cystic fibrosis by stabilizing CFTR’s first nucleotide-binding domain (NBD1).
| Headquarters | Boston, MA |
| Website | sionnatx.com |
| Pipeline | Preclinical |
| @sionna_tx | |
| Sionna Therapeutics |